Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
GLP-1 helps to slow digestion and increase satiety, whereas GIP helps enhance insulin secretion and regulate appetite
Semaglutide, a GLP-1 receptor agonist, is the active ingredient in popular medications like Ozempic, Wegovy, and Rybelsus
You want to start treatment quickly without months of insurance paperwork
Half-life, StatPearls (2023) Semaglutide, StatPearls (2024) Drug elimination, StatPearls (2023) Antidotes, Medscape Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system, Frontiers in Public Health (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity, and Metabolism (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Russian firm to invest $80 million in Pakistan to produce insulin with local partner Project includes plants to produce insulin locally from its active ingredient by 2031 DRAP approves prices for Russian insulin, links them to local production commitment KARACHI: Russian firm Zavod Medsintez LLC and its local importer Genetics Pharmaceuticals Private Limited plan to invest about $80 million in Pakistans pharmaceutical sector over the next six years to start producing insulin locally, according to a notification the Drug Regulatory Authority of Pakistan (DRAP) shared with Arab News on Tuesday
US$ 25.90
US$ 21.10
US$ 24.11
US$ 29.77
US$ 23.51
US$ 24.75
